Prostate cancer classification
First Claim
1. A method of treating prostate cancer in a subject in need thereof, comprising:
- a) obtaining a prostate cancer sample of a tissue from a subject, wherein the tissue is already known to be a prostate cancer, wherein the prostate cancer sample comprises cancer cells and normal cells;
b) measuring the expression level of p53 and DNA Damage-Regulated Protein 1 (PDRG1) in the cancer cells from the prostate cancer sample and in the normal cells from the same prostate cancer sample;
c) comparing the expression levels of PDRG1 in the cancer cells to the normal cells;
d) detecting a significant increase in expression of PDRG1 in the cancer cells relative to the normal cells;
e) characterizing and/or prognosing the subject as having an increased likelihood of cancer recurrence and/or an increased likelihood of cancer metastasis; and
f) administering a chemotherapeutic agent or radiotherapy to said subject of part (e), or carrying out prostate cancer removal surgery on said subject of part (e).
2 Assignments
0 Petitions
Accused Products
Abstract
A method is provided for characterizing and/or prognosing prostate cancer in a subject comprising determining the expression level of at least one of CREM, ERRFI1, SRSF5, PDK4, HJURP, PDRG1, TRPM3, PDE4D, FI2, ADAMTS1, ADAMTS9, B3GNT5, CD38, CEBPD, CENPF, DKK1, EMP1, F3, IL1R1, IL8, JUNB, KLFIO, KLF4, LDLR, LGALS3, LPARI, MALAT1, MTUS1, MYBPC1, NFIL3, NR4A3, OAT, PI15, PTGS2, RHOBTB3, RIN2, RNFT2, SELE, SLC15A2, SOCS2, SOCS3, SSTR1, ST6GAL1, TSC22D1, XBP1 and ZFP36 in a sample from the subject. The method may be used to predict the likelihood of metastasis. Also disclosed are methods for diagnosing and selecting treatment for prostate cancer, together with corresponding methods of treatment. Systems, kits and computer programs for performing the methods are also provided.
41 Citations
10 Claims
-
1. A method of treating prostate cancer in a subject in need thereof, comprising:
-
a) obtaining a prostate cancer sample of a tissue from a subject, wherein the tissue is already known to be a prostate cancer, wherein the prostate cancer sample comprises cancer cells and normal cells; b) measuring the expression level of p53 and DNA Damage-Regulated Protein 1 (PDRG1) in the cancer cells from the prostate cancer sample and in the normal cells from the same prostate cancer sample; c) comparing the expression levels of PDRG1 in the cancer cells to the normal cells; d) detecting a significant increase in expression of PDRG1 in the cancer cells relative to the normal cells; e) characterizing and/or prognosing the subject as having an increased likelihood of cancer recurrence and/or an increased likelihood of cancer metastasis; and f) administering a chemotherapeutic agent or radiotherapy to said subject of part (e), or carrying out prostate cancer removal surgery on said subject of part (e). - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
-
Specification